Amneal Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amneal Pharmaceuticals (AMRX) Misses Q2 EPS by 1c; Offers FY22 Guidance
August 5, 2022 6:02 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q2 EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $559 million versus the consensus estimate of $534.44 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.81. Amneal... More
